Results of Operations and Financial Condition. On August 12, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhi…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), Nasdaq has dete…

Results of Operations and Financial Condition. On May 13, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 h…

Regulation FD Disclosure. ​ On April 1, 2026, Aprea Therapeutics, Inc. issued a press release regarding the closing of its previously announced private placement for gross proceeds of approximately $30 million. The press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. ​ The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amen…

Entry Into a Material Definitive Agreement. On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to approximately 37.2 million shares (the…

The Common Warrants, the Pre-Funded Warrants, and the shares of common stock underlying the Common Warrants and the Pre-Funded Warrants (collectively, the “ Securities ”) were, and will be, offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Each Purchaser is an “accredited investor,” as defined in Regulation D, and is acquiring the Securities for investment only and not with a vi…

Results of Operations and Financial Condition. On March 16, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, includin…

Entry Into a Material Definitive Agreement. On January 28, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares (the “ Private Placement Shares ”) of the Company’s Common Stock, par value $0.001 per share (“ Common Stock…

The Private Placement Shares, the Common Warrants, the Pre-Funded Warrants, and the shares of common stock underlying the Common Warrants and the Pre-Funded Warrants (collectively, the “ Securities ”) were, and will be, offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Each Purchaser is an “accredited investor,” as defined in Regulation D, and is acquiring the Securities for inv…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing o…

The Private Placement Shares, the Common Warrants, the Pre-Funded Warrants, the Placement Agent Warrants, and the shares of common stock underlying the Common Warrants, the Placement Agent Warrants, and the Pre-Funded Warrants (collectively, the “Securities”) were, and will be, offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Each Purchaser is an “accredited investor,” as defin…

Entry Into a Material Definitive Agreement. On December 8, 2025, Aprea Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors and Company insiders (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 2,623,023 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.001 per share (“C…

Results of Operations and Financial Condition. On November 12, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, includ…

Results of Operations and Financial Condition. On August 12, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhi…

Results of Operations and Financial Condition. On May 14, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2025, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 h…

Results of Operations and Financial Condition. On March 25, 2025, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2024, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, includin…

John P. Hamill: The amendment to the Employment Agreement provides enhanced severance benefits for Mr. Hamill.

Results of Operations and Financial Condition. On January 13, 2025, Aprea Therapeutics, Inc. (the “Company”) posted an updated corporate presentation slide deck (the “Corporate Presentation”) to its website. In the Corporate Presentation, the Company disclosed that, as of December 31, 2024, it had a cash and cash equivalents balance of $22,800,000. The foregoing financial information is unaudited and preliminary, does not present all information necessary for an understanding of the Company’s…

Entry into a Material Definitive Agreement. On November 8, 2024, Aprea Therapeutics, Inc. (the “Company”) entered into an at the market offering agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “HCW”). Under the Sales Agreement, the Company may offer and sell its common stock, par value $0.001 per share (“Common Stock”), from time to time having an aggregate offering price of up to $3.0 million (the “Shares”) during the term of the Sales Agreement through or to HCW as sa…

Results of Operations and Financial Condition. On November 7, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2024, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibi…

Results of Operations and Financial Condition. Aprea Therapeutics, Inc. (the “Company”) is currently finalizing its financial quarterly closing process for the three months ended September 30, 2024. While complete financial information and operating data are not yet available, the Company expects cash and cash equivalents to be approximately $26.2 million as of September 30, 2024, down sequentially as compared to approximately $28.7 million as of June 30, 2024. This estimate of cash and cash…

Results of Operations and Financial Condition. On August 12, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2024, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1…

Results of Operations and Financial Condition. On May 14, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, including Exhibit 99.1 h…

Results of Operations and Financial Condition. On March 26, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023, and provided an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in this Item 2.02, includin…

Entry Into a Material Definitive Agreement. On March 11, 2024, Aprea Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.001 per share (“Common Stock”) at a purc…